钠-葡萄糖共转运体2型抑制剂与心律失常的关系及进展

吴金春; 刘韬; 黄从新

doi:10.13201/j.issn.1001-1439.2022.08.015

钠-葡萄糖共转运体2型抑制剂与心律失常的关系及进展

- 武汉大学人民医院心内科武汉大学心血管病研究所心血管病湖北省重点实验室(武汉，430060)
基金项目:
湖北省技术创新专项重大项目(No：2016ACA153)；青海省科技厅应用基础研究项目(2022-ZJ-758)

详细信息

通讯作者: 黄从新，E-mail：huangcongxin@vip.163.com

中图分类号: R541.7

收稿日期: 2021-11-17

刊出日期: 2022-08-13

The relationship and research progress of sodium glucose cotransporter 2 inhibitors and arrhythmia

- Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, 430060, China

More Information

Corresponding author: HUANG Congxin, E-mail: huangcongxin@vip.163.com

Received Date: 17 November 2021

Publish Date: 13 August 2022

摘要

摘要: 钠-葡萄糖共转运体2型抑制剂(SGLT2i)是一种具有较好的心血管及肾脏保护作用的新型口服降糖药，相关基础及临床研究报道SGLT2i也具有较好的抗心律失常作用，然而其具体机制尚不明确，目前亦无SGLT2i抗心律失常作用的直接研究证据报告，其中关于SGLT2i对NHE1活性和Na⁺平衡的报道尚不一致。本文复习归纳国内外关于SGLT2i抑制心律失常的相关文献报道，结合最新研究证据，就SGLT2i与抑制心律失常相关的临床证据、实验研究以及可能的机制等作一综述。
- 钠-葡萄糖共转运体2型抑制剂 /
- 心律失常 /
- 心房颤动 /
- 室性心律失常
Abstract: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a novel type of oral hypoglycemic agent with cardiovascular and renal protection. SGLT2i has also been found to have anti-arrhythmic properties in basic and clinical research. However, the mechanism behind this action is unknown, no direct research evidence demonstrating the anti-arrhythmic effect of SGLT2i has been discovered, and reports on NHE1 activity and salt balance impact of SGLT2i are still conflicting. This paper assesses both the domestic and foreign literature and review the research progress of SGLT2 and cardiac arrhythmia prevention.
- sodium glucose cotransporter 2 inhibitor /
- arrhythmia /
- atrial fibrillation /
- ventricular arrhythmia

HTML全文

参考文献(48)

[1]	Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect[J]. Cardiovasc Diabetol, 2020, 19(1): 98. doi: 10.1186/s12933-020-01071-y
[2]	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2019, 380(4): 347-357. doi: 10.1056/NEJMoa1812389
[3]	中国心衰中心联盟. 舒张性心力衰竭早期防治专家建议[J]. 临床心血管病杂志, 2021, 37(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202101001.htm
[4]	Banerjee SK, McGaffin KR, Pastor-Soler NM, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states[J]. Cardiovasc Res, 2009, 84(1): 111-118. doi: 10.1093/cvr/cvp190
[5]	Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members[J]. Diabetes Ther, 2010, 1(2): 57-92. doi: 10.1007/s13300-010-0006-4
[6]	Zelniker TA, Bonaca MP, Furtado R, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial[J]. Circulation, 2020, 141(15): 1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183
[7]	Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials[J]. Heart Rhythm, 2021, 18(7): 1098-1105. doi: 10.1016/j.hrthm.2021.03.028
[8]	Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats[J]. Cardiovasc Diabetol, 2019, 18(1): 165. doi: 10.1186/s12933-019-0964-4
[9]	Mustroph J, Wagemann O, Lücht CM, et al. Empagliflozin reduces Ca/calmodulin-dependent kinase Ⅱ activity in isolated ventricular cardiomyocytes[J]. ESC Heart Fail, 2018, 5(4): 642-648. doi: 10.1002/ehf2.12336
[10]	Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF[J]. Eur Heart J, 2021, 42(36): 3727-3738. doi: 10.1093/eurheartj/ehab560
[11]	Li D, Liu Y, Hidru TH, et al. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials[J]. Front Endocrinol(Lausanne), 2021, 12: 619586. doi: 10.3389/fendo.2021.619586
[12]	Li HL, Lip G, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors(SGLT2i)and cardiac arrhythmias: a systematic review and meta-analysis[J]. Cardiovasc Diabetol, 2021, 20(1): 100. doi: 10.1186/s12933-021-01293-8
[13]	Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis[J]. Cardiovasc Res, 2004, 61(2): 208-217. doi: 10.1016/j.cardiores.2003.11.018
[14]	Bode D, Semmler L, Wakula P, et al. Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF[J]. Cardiovasc Diabetol, 2021, 20(1): 7. doi: 10.1186/s12933-020-01208-z
[15]	Lee TI, Chen YC, Lin YK, et al. Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats[J]. Int J Mol Sci, 2019, 20(7).
[16]	Vila-Petroff M, Mundiña-Weilenmann C, Lezcano N, et al. Ca²⁺/calmodulin-dependent protein kinase Ⅱ contributes to intracellular pH recovery from acidosis via Na⁺/H⁺exchanger activation[J]. J Mol Cell Cardiol, 2010, 49(1): 106-112. doi: 10.1016/j.yjmcc.2009.12.007
[17]	Hamouda NN, Sydorenko V, Qureshi MA, et al. Dapagliflozin reduces the amplitude of shortening and Ca(2+)transient in ventricular myocytes from streptozotocin-induced diabetic rats[J]. Mol Cell Biochem, 2015, 400(1-2): 57-68. doi: 10.1007/s11010-014-2262-5
[18]	Hess P, Lansman JB, Tsien RW. Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists[J]. Nature, 1984, 311(5986): 538-544. doi: 10.1038/311538a0
[19]	Xie W, Santulli G, Reiken SR, et al. Mitochondrial oxidative stress promotes atrial fibrillation[J]. Sci Rep, 2015, 5: 11427. doi: 10.1038/srep11427
[20]	Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na⁺through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J]. Diabetologia, 2017, 60(3): 568-573. doi: 10.1007/s00125-016-4134-x
[21]	Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial[J]. N Engl J Med, 1991, 324(12): 781-788. doi: 10.1056/NEJM199103213241201
[22]	Filippatos TD, Liontos A, Papakitsou I, et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses[J]. Postgrad Med, 2019, 131(2): 82-88. doi: 10.1080/00325481.2019.1581971
[23]	Bertero E, Prates Roma L, Ameri P, et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis[J]. Cardiovasc Res, 2018, 114(1): 12-18. doi: 10.1093/cvr/cvx149
[24]	Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation[J]. Diabetologia, 2018, 61(3): 722-726. doi: 10.1007/s00125-017-4509-7
[25]	Philippaert K, Kalyaanamoorthy S, Fatehi M, et al. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin[J]. Circulation, 2021, 143(22): 2188-2204. doi: 10.1161/CIRCULATIONAHA.121.053350
[26]	Chung YJ, Park KC, Tokar S, et al. Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na⁺/H⁺ exchanger-1 or lower[Na⁺]i in the heart[J]. Cardiovasc Res, 2021, 117(14): 2794-2806. doi: 10.1093/cvr/cvaa323
[27]	Van Steenbergen A, Balteau M, Ginion A, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart[J]. Sci Rep, 2017, 7: 41166. doi: 10.1038/srep41166
[28]	周子华. 新型降糖药物的降压作用[J]. 临床心血管病杂志, 2021, 37(8): 692-694. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202108002.htm
[29]	Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2010, 55(13): 1318-1327. doi: 10.1016/j.jacc.2009.10.061
[30]	Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study[J]. Cardiovasc Diabetol, 2017, 16(1): 138. doi: 10.1186/s12933-017-0621-8
[31]	Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics[J]. J Am Coll Cardiol, 2019, 73(15): 1931-1944. doi: 10.1016/j.jacc.2019.01.056
[32]	Durak A, Olgar Y, Degirmenci S, et al. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats[J]. Cardiovasc Diabetol, 2018, 17(1): 144. doi: 10.1186/s12933-018-0790-0
[33]	Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications[J]. Circulation, 2016, 134(10): 752-772. doi: 10.1161/CIRCULATIONAHA.116.021887
[34]	Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3(Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure[J]. Circ Heart Fail, 2020, 13(1): e006277. doi: 10.1161/CIRCHEARTFAILURE.119.006277
[35]	Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats[J]. Cardiovasc Diabetol, 2019, 18(1): 45. doi: 10.1186/s12933-019-0849-6
[36]	Xue L, Yuan X, Zhang S, et al. Investigating the Effects of Dapagliflozin on Cardiac Function, Inflammatory Response, and Cardiovascular Outcome in Patients with STEMI Complicated with T2DM after PCI[J]. Evid Based Complement Alternat Med, 2021, 2021: 9388562.
[37]	Tanaka H, Soga F, Tatsumi K, et al. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure[J]. Cardiovasc Diabetol, 2020, 19(1): 6. doi: 10.1186/s12933-019-0985-z
[38]	Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity[J]. J Cardiol, 2018, 71(5): 471-476. doi: 10.1016/j.jjcc.2017.12.004
[39]	Zhang N, Feng B, Ma X, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2019, 18(1): 107.
[40]	Wan N, Rahman A, Hitomi H, et al. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity[J]. Front Endocrinol(Lausanne), 2018, 9: 421.
[41]	Chhabra KH, Morgan DA, Tooke BP, et al. Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice[J]. Mol Metab, 2017, 6(10): 1274-1285.
[42]	Park SH, Farooq MA, Gaertner S, et al. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat[J]. Cardiovasc Diabetol, 2020, 19(1): 19.
[43]	Lee PC, Ganguly S, Goh SY. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms[J]. Obes Rev, 2018, 19(12): 1630-1641.
[44]	Mirabelli M, Chiefari E, Caroleo P, et al. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus[J]. J Diabetes Res, 2019, 2019: 3971060.
[45]	Deerochanawong C, Chan SP, Matawaran BJ, et al. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations[J]. Diabetes Obes Metab, 2019, 21(11): 2354-2367.
[46]	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306.
[47]	Ye Y, Zhao C, Liang J, et al. Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk[J]. Front Pharmacol, 2018, 9: 1517.
[48]	Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor[J]. N Engl J Med, 2017, 376(23): 2300-2302.